BioLineRx (BLRX) Long-Term Debt Repayments (2013 - 2021)
BioLineRx's (BLRX) quarterly Long-Term Debt Repayments came in at -$874000.0 in Q4 2021, down 9.94% year-on-year from -$970433.0 in Q4 2020, and down 2.34% quarter-over-quarter from -$854000.0 in Q3 2021.
BioLineRx (BLRX) Long-Term Debt Repayments (2013 - 2021) Analysis & Trends
BioLineRx's Long-Term Debt Repayments history runs 8 years deep, the most recent figure standing at -$874000.0 for Q4 2021.
- On a quarterly basis, Long-Term Debt Repayments fell 9.94% year-over-year to -$874000.0 in Q4 2021; TTM through Dec 2021 was -$3.4 million, a 7.76% decrease from a year earlier, with the FY2023 full-year figure at -$1.5 million, up 45.52% from the prior year.
- Long-Term Debt Repayments slipped to -$874000.0 in Q4 2021 per BLRX's latest filing, from -$854000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at -$23000.0 in Q1 2017 and bottomed at -$1.0 million in Q3 2020.
- The 5-year median for Long-Term Debt Repayments is -$182500.0 (2017), against an average of -$395100.0.
- Across the five-year window, Long-Term Debt Repayments plunged 4278.26% in 2020 and gained 15.19% in 2021, its largest moves.
- Year by year, Long-Term Debt Repayments stood at -$23000.0 in 2017, then slumped by 1382.61% to -$341000.0 in 2018, then tumbled by 140.18% to -$819000.0 in 2019, then grew by 2.93% to -$795000.0 in 2020, then retreated by 9.94% to -$874000.0 in 2021.
- Per Business Quant, the three latest BLRX Long-Term Debt Repayments figures stand at -$874000.0 (Q4 2021), -$854000.0 (Q3 2021), and -$834000.0 (Q2 2021).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -874,000.00 |
| Dec 31, 2021 | -874,000.00 |
| Sep 30, 2021 | -854,000.00 |
| Sep 30, 2021 | -854,000.00 |
| Jun 30, 2021 | -834,000.00 |
| Jun 30, 2021 | -834,000.00 |
| Mar 31, 2021 | -814,000.00 |
| Mar 31, 2021 | -814,000.00 |
| Dec 31, 2020 | -795,000.00 |
| Dec 31, 2020 | -795,000.00 |
| Sep 30, 2020 | -1.01 Mn |
| Sep 30, 2020 | -1.01 Mn |
| Jun 30, 2020 | -649,000.00 |
| Jun 30, 2020 | -649,000.00 |
| Mar 31, 2020 | -682,000.00 |
| Mar 31, 2020 | -682,000.00 |
| Dec 31, 2019 | -819,000.00 |
| Dec 31, 2019 | -819,000.00 |
| Sep 30, 2019 | -23,000.00 |
| Sep 30, 2019 | -23,000.00 |